Yuhan Yue1,2, Junqing Liang2,3, Yuruo Wu3, Weibing Tong2, Dan Li1, Xuchen Cao1, Xin Wang1. 1. First Department of Breast cancer, 74675Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China. 2. Department of Breast Tumor Center, Affiliated People's Hospital of 66287Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China. 3. Department of cytotherapy for tumors, Affiliated People's Hospital of 66287Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China.
Abstract
Background: Luminal B-like human epidermal growth factor receptor 2 negative (Luminal B [HER2-]) is the most common molecular subtype of breast cancer (BC). Since the relationship between Luminal B (HER2-) BC and liver metastasis (LM) is poorly defined, this retrospective study aimed to develop an LM risk nomogram for patients with lymph node-related (N + Luminal B [HER2-]) BC. Methods: Data were obtained for patients initially diagnosed with BC from the Tianjin Medical University Cancer Institute and Hospital. There were 30,975 Chinese female patients with stage I-III BC and follow-up confirming 1217 subsequent patients with LM, and 427 patients with N + Luminal B (HER2-). The LM risk was assessed using Cox proportional hazards regression, histogram, Venn diagram, and Kaplan-Meier survival analysis, with further analysis for patients with N + Luminal B (HER2-) BC. A nomogram was established based on the N + Luminal B (HER2-) BC data, which was validated using calibration plots. Results: The median age of 427 patients with N + Luminal B (HER2-) liver metastasis of breast cancer (BCLM) was 49 years. The largest number of patients with BCLM was diagnosed between the second to the 6th year, the longest interval from initial BC diagnosis to subsequent LM was 145 months. The patients with LM as the first site of distant metastasis which is associated with better survival were analyzed by Kaplan-Meier. The nomogram was constructed for the risk of LM that included age, menstrual status, unilateral oophorectomy, pregnancy, hepatitis B antigen, region of residence, tumor size, lymph node, clavicular lymph nodes, progesterone receptor, and lymph vessel invasion. Conclusion: We described the clinicopathological characteristics of patients with stage I-III BC, and constructed a nomogram for calculating personalized LM probabilities for patients with N + Luminal B (HER2-), which could guide future prolonged or early extensive treatment decisions.
Background: Luminal B-like human epidermal growth factor receptor 2 negative (Luminal B [HER2-]) is the most common molecular subtype of breast cancer (BC). Since the relationship between Luminal B (HER2-) BC and liver metastasis (LM) is poorly defined, this retrospective study aimed to develop an LM risk nomogram for patients with lymph node-related (N + Luminal B [HER2-]) BC. Methods: Data were obtained for patients initially diagnosed with BC from the Tianjin Medical University Cancer Institute and Hospital. There were 30,975 Chinese female patients with stage I-III BC and follow-up confirming 1217 subsequent patients with LM, and 427 patients with N + Luminal B (HER2-). The LM risk was assessed using Cox proportional hazards regression, histogram, Venn diagram, and Kaplan-Meier survival analysis, with further analysis for patients with N + Luminal B (HER2-) BC. A nomogram was established based on the N + Luminal B (HER2-) BC data, which was validated using calibration plots. Results: The median age of 427 patients with N + Luminal B (HER2-) liver metastasis of breast cancer (BCLM) was 49 years. The largest number of patients with BCLM was diagnosed between the second to the 6th year, the longest interval from initial BC diagnosis to subsequent LM was 145 months. The patients with LM as the first site of distant metastasis which is associated with better survival were analyzed by Kaplan-Meier. The nomogram was constructed for the risk of LM that included age, menstrual status, unilateral oophorectomy, pregnancy, hepatitis B antigen, region of residence, tumor size, lymph node, clavicular lymph nodes, progesterone receptor, and lymph vessel invasion. Conclusion: We described the clinicopathological characteristics of patients with stage I-III BC, and constructed a nomogram for calculating personalized LM probabilities for patients with N + Luminal B (HER2-), which could guide future prolonged or early extensive treatment decisions.
Entities:
Keywords:
Chinese female patient; breast cancer; liver metastasis; luminal B(HER2−); lymph node positive; nomogram
Authors: Rita Nanda; Minetta C Liu; Christina Yau; Rebecca Shatsky; Lajos Pusztai; Anne Wallace; A Jo Chien; Andres Forero-Torres; Erin Ellis; Heather Han; Amy Clark; Kathy Albain; Judy C Boughey; Nora T Jaskowiak; Anthony Elias; Claudine Isaacs; Kathleen Kemmer; Teresa Helsten; Melanie Majure; Erica Stringer-Reasor; Catherine Parker; Marie C Lee; Tufia Haddad; Ronald N Cohen; Smita Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Katherine Steeg; Adam Asare; Jeffrey B Matthews; Scott Berry; Ashish Sanil; Richard Schwab; W Fraser Symmans; Laura van 't Veer; Douglas Yee; Angela DeMichele; Nola M Hylton; Michelle Melisko; Jane Perlmutter; Hope S Rugo; Donald A Berry; Laura J Esserman Journal: JAMA Oncol Date: 2020-05-01 Impact factor: 31.777
Authors: Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen A Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs Journal: J Clin Oncol Date: 2018-11-19 Impact factor: 44.544
Authors: Peter Schmid; Hope S Rugo; Sylvia Adams; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Vidya Maiya; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: Lancet Oncol Date: 2019-11-27 Impact factor: 41.316
Authors: C Dilara Savci-Heijink; Hans Halfwerk; Gerrit K J Hooijer; Hugo M Horlings; Jelle Wesseling; Marc J van de Vijver Journal: Breast Cancer Res Treat Date: 2015-03-29 Impact factor: 4.872